{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:21:27Z","timestamp":1752229287024},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,1,25]],"date-time":"2014-01-25T00:00:00Z","timestamp":1390608000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s11940-013-0280-3","type":"journal-article","created":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T10:51:01Z","timestamp":1390560661000},"source":"Crossref","is-referenced-by-count":5,"title":["Urologic Agents for Treatment of Bladder Dysfunction in Neurologic Disease"],"prefix":"10.1007","volume":"16","author":[{"given":"Eliza","family":"Lamin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariana L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,25]]},"reference":[{"key":"280_CR1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11884-010-0077-0","volume":"6","author":"LG Stansell","year":"2011","unstructured":"Stansell LG, Smith AL, Jaffe WI. Treatment of neurogenic voiding dysfunction: an update. Curr Bladder Dysfunct Rep. 2011;6:37\u201344.","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"280_CR2","volume-title":"Campbell-Walsh Urology","year":"2007","unstructured":"Campbell MF, Wein AJ, Kavoussi LR, editors. Campbell-Walsh Urology. Philadelphia: Saunders\/Elsevier; 2007."},{"issue":"4 Pt. 1","key":"280_CR3","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.juro.2006.06.009","volume":"176","author":"TM Kessler","year":"2006","unstructured":"Kessler TM, Studer UE, Burkhard FC. The effect of terazosin on functional bladder outlet obstruction in women: a pilot study. J Urol. 2006;176(4 Pt. 1):1487.","journal-title":"J Urol"},{"issue":"1","key":"280_CR4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","volume":"174","author":"B Schurch","year":"2005","unstructured":"Schurch B, de S\u00e8ze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196\u2013200.","journal-title":"J Urol"},{"issue":"6","key":"280_CR5","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.juro.2012.11.175","volume":"189","author":"KM Peters","year":"2013","unstructured":"Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol. 2013;189(6):2194\u2013201. This study shows the effectiveness of PTNS over long term, it had already been shown to be effective in the short term but this study was the first well made study that showed the use of PTNS over a longer time period.","journal-title":"J Urol"},{"key":"280_CR6","volume-title":"Epocrates essentials (13.9.1 ed.)","author":"AthenaHealth","year":"2013","unstructured":"AthenaHealth. Epocrates essentials (13.9.1 ed.). United States: Epocrates, Inc.; 2013."},{"key":"280_CR7","unstructured":"Walters Kluwer Health. (2013). Lexicomp."},{"issue":"6","key":"280_CR8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1742-1241.2006.00987.x","volume":"60","author":"R Roberts","year":"2006","unstructured":"Roberts R, Bavendam T, Glasser DB, Carlsson M, Eyland N, Elinoff V. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract. 2006;60(6):752\u20138.","journal-title":"Int J Clin Pract"},{"issue":"4","key":"280_CR9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2008.06.080","volume":"54","author":"G Novara","year":"2008","unstructured":"Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54(4):740\u201363.","journal-title":"Eur Urol"},{"issue":"4","key":"280_CR10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.eururo.2007.05.027","volume":"52","author":"CR Chapple","year":"2007","unstructured":"Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, et al. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5\u00a0mg and tolterodine ER 4\u00a0mg. Eur Urol. 2007;52(4):1195\u2013203.","journal-title":"Eur Urol"},{"issue":"1","key":"280_CR11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1464-410X.2008.07710.x","volume":"102","author":"CJ Kelleher","year":"2008","unstructured":"Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int. 2008;102(1):56\u201361.","journal-title":"BJU Int"},{"issue":"3","key":"280_CR12","first-page":"935","volume":"10","author":"M Imran","year":"2013","unstructured":"Imran M, Najmi AK, Tabrez S. Mirabegron for overactive bladder: a novel, first-in-class \u03b23 -agonist therapy. Urol J. 2013;10(3):935\u201340. This study is the first to use \u03b23 agonists in the treatment of overactive bladder. It is truly a novel approach.","journal-title":"Urol J"},{"issue":"5","key":"280_CR13","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2012.02.036","volume":"62","author":"P Madhuvrata","year":"2012","unstructured":"Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: A systematic review and meta-analysis. Eur Urol. 2012;62(5):816\u201330.","journal-title":"Eur Urol"},{"issue":"3","key":"280_CR14","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.juro.2009.05.038","volume":"182","author":"AP Cameron","year":"2009","unstructured":"Cameron AP, Clemens JQ, Latini JM, McGuire EJ. Combination drug therapy improves compliance of the neurogenic bladder. J Urol. 2009;182(3):1062\u20137.","journal-title":"J Urol"},{"issue":"4","key":"280_CR15","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.juro.2007.11.060","volume":"179","author":"Y Low","year":"2008","unstructured":"Low Y, Liong ML, Yuen KH, et al. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double blind, placebo controlled trial. J Urol. 2008;179(4):1461.","journal-title":"J Urol"},{"issue":"6","key":"280_CR16","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.juro.2009.08.031","volume":"182","author":"NY Siddiqui","year":"2009","unstructured":"Siddiqui NY, Amundsen CL, Visco AG, Myers ER, Wu JM. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol. 2009;182(6):2799\u2013804.","journal-title":"J Urol"},{"issue":"2","key":"280_CR17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/01443610903428922","volume":"30","author":"AE Ridout","year":"2010","unstructured":"Ridout AE, Yoong W. Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy. J Obstet Gynaecol. 2010;30(2):111\u20134.","journal-title":"J Obstet Gynaecol"},{"issue":"1","key":"280_CR18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.juro.2012.08.085","volume":"189","author":"M Martinson","year":"2013","unstructured":"Martinson M, MacDiarmid S, Black E. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. J Urol. 2013;189(1):210\u20136. This study compared two very commonly used methods of treating bladder dysfunction. Its importance is in showing the cost-effectiveness of both methods, and it showed that although initially PTNS is more cost-effective, over time SNS also becomes cost-effective.","journal-title":"J Urol"},{"issue":"1","key":"280_CR19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.juro.2011.09.052","volume":"187","author":"HW Chen","year":"2012","unstructured":"Chen HW, Bercik RS, Werner EF, Thung SF. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder. J Urol. 2012;187(1):178\u201384. This study compared pharmacologic procedures with interventional procedures. While pharmacologic treatments are initially more cost-effective, it turns out that in the long-term, an interventional procedure, while costly at first, can become the more cost-effective option.","journal-title":"J Urol"},{"issue":"4, Supplement","key":"280_CR20","first-page":"e560","volume":"189","author":"J Jenks","year":"2013","unstructured":"Jenks J, Hamid R, Shah J, Greenwell T, Betts C, Walleser S, et al. 1368 sacral nerve stimulation (SNS) for the treatment of idiopathic refractory overactive bladder: cost-effectiveness compared to optimal medical therapy, botulinum toxin a (boNT-A) and percutaneous tibial nerve stimulation (PTNS). J Urol. 2013;189(4, Supplement):e560.","journal-title":"J Urol"},{"issue":"19","key":"280_CR21","first-page":"86","volume":"79","author":"V Maurelli","year":"2012","unstructured":"Maurelli V, Petta F, Carsillo G, Miano R, Lamorte F, Perugia C, et al. [What to do if percutaneous tibial nerve stimulation (PTNS) works? A pilot study on home-based transcutaneous tibial nerve stimulation\u2013 Urologia. 2012;79(19):86\u201390.","journal-title":"A pilot study on home-based transcutaneous tibial nerve stimulation\u2013 Urologia"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-013-0280-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-013-0280-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-013-0280-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:57:00Z","timestamp":1559437020000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-013-0280-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,25]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1007\/s11940-013-0280-3","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,25]]},"article-number":"280"}}